Pegasus Laboratories, Inc. FDA Inspection Record
Pegasus Laboratories, Inc. is an FDA-registered facility (FEI 1038896) located in Pensacola, FL, US. Registered operations: ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE. RegDataLab tracks 5 FDA inspections and 1 compliance action at this facility.
What FDA found at this site
- Latest inspection
- Jun 11, 2026: No Action Indicated (NAI)
- Inspections on record
- 5 (1 VAI, 4 NAI)
- Last OAI inspection
- None on record
- Warning letters
- 1 listed by FDA for this FEI, latest Aug 5, 2016
- Recalls as the recalling firm
- 9, latest Jul 20, 2026
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Jun 11, 2026 | No Action Indicated (NAI) | No citations listed |
| Feb 24, 2023 | Voluntary Action Indicated (VAI) | Procedures not in writing, fully followed (21 CFR 211.22(d)) Scientifically sound laboratory controls (21 CFR 211.160(b)) Calibration - at intervals, written program, remedial action (21 CFR 211.160(b)(4)) Written record of investigation incomplete (21 CFR 211.192) |
| Dec 22, 2016 | No Action Indicated (NAI) | No citations listed |
| May 27, 2014 | No Action Indicated (NAI) | No citations listed |
| Dec 8, 2011 | No Action Indicated (NAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Jul 20, 2026 | Class II | V-0183-2026 | Proin ER, phenylpropanolamine hydrochloride extended-release tablets, 145mg Tablets, Net… Failed dissolution specifications |
| Sep 12, 2025 | Class II | V-0112-2025 | PROIN ER, (Phenylpropanolamine hydrochloride extended-release tablets), 145 mg, net… An out of specification result was confirmed after data review in dissolution testing for Proin ER 145mg lot 25079A1 (ST10431 - 3 mo. @ CRT)… |
| Jun 24, 2025 | Class II | V-0102-2025 | Firocoxib Tablets for Horses, 57mg, 60 Tablets, Manufactured by: Pegasus Laboratories… Out of specification result obtained for dissolution at 120 minutes. |
| Jan 20, 2025 | Class II | V-0058-2025 | Rebalance, Antiprotozoal Oral Suspension, sulfadiazine and pyrimethamine, Net Contents… Due to a 3-month CRT stability failure for low Pyrimethamine Assay due to non-uniformity across the batch |
| Dec 29, 2023 | Class III | V-0031-2024 | Proin ER" (phenylpropanolamine hydrochloride
extended-release tablets) 145 mg Due to multiple complaints (broken tablets) and a 3-month CRT stability failure for hardness. |
| Jun 9, 2023 | Class II | V-0140-2023 | Proin 50 mg (phenylpropanolamine hydrochloride) Chewable Tablets 50 mg per tablet… and 7 more products Product stored at extreme temperatures during storage. |
| Oct 21, 2020 | Class II | V-0026-2021 | Proin ER (phenylpropanolamine hydrochloride extended-release tablets) 145 mg Manufactured… Out of specification for microbial limits. |
| Jul 10, 2014 | Class II | V-167-2014 | ReBalance Antiprotozoal Oral Suspension (Sulfadiazine and Pyrimethamine
For Oral Use in… Low assay result for the Pyrimethamine at the 6-month stability time point. |
| May 24, 2012 | Class II | V-168-2012 | PROIN 75MG COUNT BOTTLES HAVE THE CORRECT BASE LABEL OF: "***PROIN 75 mg… Pegasus Laboratories, Inc. is recalling 75 mg, 60 count bottles of Proin Lots 120416 and 120213 for misbranding. The affected product has… |
FDA record score
23 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
10 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall V-0183-2026, this FEI as the recalling firm | Jul 20, 2026 | 4 x 1 | 4 |
| Class II recall V-0112-2025, this FEI as the recalling firm | Sep 12, 2025 | 4 x 1 | 4 |
| Class II recall V-0102-2025, this FEI as the recalling firm | Jun 24, 2025 | 4 x 1 | 4 |
| Class II recall V-0058-2025, this FEI as the recalling firm | Jan 20, 2025 | 4 x 1 | 4 |
| Inspection classified VAI | Feb 24, 2023 | 6 x 0.6 | 3.6 |
| Class II recall V-0140-2023, this FEI as the recalling firm | Jun 9, 2023 | 4 x 0.6 | 2.4 |
| Class II recall V-0026-2021, this FEI as the recalling firm | Oct 21, 2020 | 4 x 0.25 | 1 |
| Warning letter on FDA's dashboard, which does not show close-outs | Aug 5, 2016 | 10 years or older, so it adds no points | 0 |
| Class II recall V-167-2014, this FEI as the recalling firm | Jul 10, 2014 | 10 years or older, so it adds no points | 0 |
| Class II recall V-168-2012, this FEI as the recalling firm | May 24, 2012 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 17, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 17, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 17, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 17, 2026 | Newest record Nov 16, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Pegasus Laboratories, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Pegasus Laboratories, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Pegasus Laboratories, Inc.
- Location
- Pensacola, FL (US)
- Registration Expires
- Dec 31, 2026
- Operations
- ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE
- Source
- decrs